Brainsway Ltd. Stock Price, News & Analysis

BrainsWay Ltd. (NASDAQ: BWAY) announced it will report its first-quarter financial results and operational highlights on May 11, 2022, before U.S. markets open. The company will host a conference call at 8:30 AM ET to discuss the results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders and is known for its FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, with indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

BrainsWay Ltd. (NASDAQ: BWAY) appoints Dr. Joachim Seidel as the new Vice President of Corporate Development and Strategy, effective March 28, 2022. With over 20 years in the medical device sector, Dr. Seidel aims to drive strategic opportunities and enhance corporate development initiatives globally. His background includes leadership roles at Covidien, Medtronic, and PAREXEL, with a proven track record in market expansion and M&A. The company's focus on expanding its Deep TMS therapy aligns with its commitment to maximize stakeholder value.

BrainsWay Ltd. (NASDAQ: BWAY) announced a KOL webinar on Deep TMS™ Therapy for anxious depression set for March 22, 2022, at 10:30 am ET. KOL Shan H. Siddiqi, M.D. from Harvard Medical School will discuss the treatment landscape for anxious depression, where 60-90% of patients with major depressive disorder also experience anxiety. BrainsWay’s patented therapy is proven to reduce anxiety symptoms in depressed patients. Interested participants can register here.

BrainsWay Ltd. (NASDAQ: BWAY) reported a 34% revenue growth in 2021, reaching $29.7 million, compared to $22.1 million in 2020. Fourth-quarter revenues rose 20% to $8.5 million. The company improved its cash position to $57.3 million, reflecting positive operational cash flow. Notably, BrainsWay received a Local Coverage Determination from Medicare, expanding coverage for Deep TMS therapy to 60 million patients. Gross margins remained steady at 77%, while operating expenses increased to $8.0 million. The net loss for the year was $6.5 million.

Burlington, Mass., and Jerusalem, March 01, 2022 - BrainsWay Ltd. (NASDAQ: BWAY) announced that CEO Christopher von Jako, Ph.D., will present at the 32nd Annual Oppenheimer Healthcare Conference. The event will take place from March 15 to March 17, 2022, with BrainsWay's presentation scheduled for March 16 at 2:40 PM ET. The company specializes in noninvasive neurostimulation treatments for mental health disorders, including major depressive disorder and obsessive-compulsive disorder. Investors interested in meetings should contact their Oppenheimer representative.

BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2022 – BrainsWay Ltd. (NASDAQ: BWAY) will report its fourth quarter and full year 2021 financial results on March 9, 2022, before U.S. markets open. A conference call and webcast, scheduled for 8:30 AM ET, will discuss the results and operational updates. BrainsWay is a leader in noninvasive neurostimulation for mental health, with FDA-cleared treatments for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company aims to raise awareness and access to its Deep TMS technology, supported by robust clinical evidence.

BrainsWay Ltd. (NASDAQ: BWAY) announced new research validating its Deep TMS™ treatment for anxiety symptoms associated with depression. The analysis, published in the Journal of Clinical Medicine, analyzed data from multiple trials, revealing that Deep TMS is significantly effective for patients with high anxiety, a group traditionally seen as less responsive to treatment. These findings enhance BrainsWay's leadership in psychiatric care, providing potential hope for the many patients experiencing anxious depression, which affects an estimated 13 to 19 million adults in the U.S. annually.

BURLINGTON, Mass. and JERUSALEM, Feb. 01, 2022 – BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation for mental health disorders, announced its CEO, Christopher von Jako, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. A fireside chat is scheduled for February 15 at 9:30am ET. The company aims to enhance awareness and access to its Deep TMS technology, which treats conditions like major depressive disorder and smoking addiction. Investors interested in meetings should contact their BTIG representative.

BrainsWay Ltd. (NASDAQ: BWAY) announced that the Medicare Administrative Contractor, Palmetto GBA, will cover the Deep TMS™ system for treating Obsessive-Compulsive Disorder (OCD) in seven states, effective March 13, 2022. This coverage expands access to over 9 million additional Medicare patients, bringing the total to approximately 60 million covered lives. The decision underscores the clinical efficacy of Deep TMS for OCD treatment, aligning with the Clinical TMS Society's recommendations.